# Supraventricular Tachycardia

Manage suspected SVT by first identifying instability and QRS regularity, using vagal maneuvers and adenosine for stable regular narrow-complex rhythms, avoiding inappropriate AV-nodal blockade in pre-excited arrhythmias, and offering electrophysiology study with ablation for recurrent symptomatic disease.

**Clinical question:** How should clinicians classify, terminate, and prevent recurrence of supraventricular tachycardia?

Updated: 2026-09-15T23:01:11.730754+00:00

## What matters in practice
- Treat hypotension, heart failure, ischemic chest discomfort, or altered mental status during SVT as hemodynamic instability and perform synchronized cardioversion when vagal maneuvers or adenosine are ineffective or infeasible. [4][19]
- For a stable regular narrow-complex tachycardia, begin with vagal maneuvers and/or IV adenosine; if unsuccessful or impractical, IV beta-blocker, diltiazem, or verapamil is a guideline-supported alternative. [1][19]
- Adenosine-induced transient AV block can uncover atrial activity and distinguish atrial tachycardia from AVNRT or AVRT, but termination does not by itself prove an AV nodal reentrant mechanism. [18]
- In manifest pre-excitation, regular narrow orthodromic AVRT can be treated as regular narrow SVT, but a wide-complex or diagnostically uncertain rhythm requires caution with AV-nodal blockers. [17]
- Refer recurrent symptomatic PSVT for electrophysiology study and catheter ablation; ablation targets the AV nodal slow pathway in AVNRT and the accessory pathway in AVRT. [16]

## Classify instability before attempting rhythm termination

The first decision is whether the tachycardia itself is causing inadequate perfusion.

Obtain a 12-lead ECG whenever feasible, continuous rhythm monitoring, blood pressure, and assessment for hypotension, heart failure, chest pain, or altered mental status. These findings identify poorly tolerated SVT and support immediate treatment and arrhythmia-specialist referral rather than observation alone. [4][19]

For hemodynamically unstable SVT, perform synchronized electrical cardioversion. If the patient is stable enough for an initial attempt at vagal maneuvers or adenosine, cardioversion remains indicated when these measures are ineffective, contraindicated, or not feasible. [4][19]

Use ECG regularity and QRS width as safety gates. A regular narrow-complex tachycardia is the setting for an AV-nodal intervention strategy. A regular wide-complex tachycardia may be ventricular tachycardia, SVT with aberrancy, or accessory-pathway conduction; if the mechanism is uncertain, manage it as an undifferentiated wide-complex tachycardia rather than reflexively administering AV-nodal blockers. [17]
- Sudden onset and termination favors paroxysmal SVT; prominent neck pulsation or “shirt flapping” supports AVNRT. [19]
- Structural heart disease increases the likelihood of atrial tachycardia and should shift attention from a presumed AV nodal reentrant mechanism to rhythm documentation and etiologic assessment. [19]
- Review for reversible contributors, including electrolyte abnormalities, medication effects, and structural heart disease. [13]

*ECG and stability features that determine the immediate SVT pathway. [4][17][19]*

| Presentation | Immediate interpretation | Next action |
| --- | --- | --- |
| Hypotension, heart failure, chest pain, or altered mental status with SVT | Hemodynamically unstable tachyarrhythmia. [4] | Synchronized cardioversion; use vagal maneuvers or adenosine only if clinically feasible without delaying definitive stabilization. [4][19] |
| Regular narrow-complex tachycardia, stable | Likely AVNRT, orthodromic AVRT, or regular atrial tachycardia/flutter. [17] | Vagal maneuvers and/or IV adenosine; consider IV beta-blocker, diltiazem, or verapamil if needed. [19] |
| Wide-complex tachycardia or uncertain mechanism | Could be ventricular tachycardia, aberrant SVT, or accessory-pathway conduction. [17] | Avoid assuming benign SVT; treat as undifferentiated wide-complex tachycardia when diagnosis is uncertain. [17] |
| Irregular narrow-complex tachycardia | Consider atrial fibrillation, flutter with variable block, multifocal atrial tachycardia, or ectopy rather than typical regular PSVT. [17] | Do not apply the regular-SVT termination pathway without defining the rhythm and considering pre-excitation. [17] |

## Terminate stable regular narrow-complex SVT with AV-nodal interventions

Use interventions that transiently slow or block AV nodal conduction while preserving diagnostic information.

For stable regular SVT of unknown mechanism, perform vagal maneuvers and/or administer IV adenosine as first-line treatment. Initial management of regular narrow-complex tachycardia is generally directed at slowing AV nodal conduction. [1][19]

If adenosine is ineffective, not feasible, or the rhythm recurs, IV beta-blocker, IV diltiazem, or IV verapamil is an alternative for stable regular SVT. In one emergency-department study of spontaneous SVT, slowly infused verapamil or diltiazem converted 98% compared with 86.5% for adenosine; mean post-conversion blood pressure fell with calcium-channel blockers, and hypotension occurred in 1 of 102 patients receiving a calcium-channel blocker. [8][19]

When choosing a nondihydropyridine calcium-channel blocker, avoid rapid bolus administration in patients with marginal blood pressure. Historical rapid infusion was associated with hypotensive episodes; a slow-infusion study used verapamil at 1 mg/min and diltiazem at 2.5 mg/min, with conversion exceeding 97% and hypotension in approximately 1% of participants. [6][8]
- Use synchronized cardioversion when pharmacologic termination fails or cannot be safely used. [4][19]
- Do not include digoxin or amiodarone in the routine acute management strategy for narrow-complex tachycardia; they are not included in the 2019 ESC narrow-QRS acute-management subsection. [9][12]
- For selected patients with infrequent, well-tolerated PSVT, an oral self-administered “pill-in-the-pocket” strategy has been discussed in ACC/AHA/HRS guidance, but delayed onset limits its role outside monitored care. [10]

### Use adenosine as a diagnostic maneuver

Adenosine or a vagal maneuver transiently suppresses AV nodal conduction and may expose otherwise obscured atrial activity, helping identify atrial tachycardia when the ECG diagnosis is uncertain. Failure to terminate with AV nodal block favors an atrial tachycardia that is continuing independently of the AV node; however, adenosine can terminate focal atrial tachycardia caused by triggered activity or microreentry as well as AVNRT and AVRT. [18]
- Save pre-treatment, treatment, and post-conversion rhythm strips; P-wave morphology and AV relationship after transient AV block can guide subsequent mapping if ablation is pursued. [18]
- Do not use adenosine response alone to label a rhythm AVNRT or AVRT. [18]

*Acute treatment sequence for stable regular SVT. [1][4][8][19]*

| Step | Intervention | Decision consequence |
| --- | --- | --- |
| 1 | Vagal maneuvers. [19] | If terminated, obtain a sinus-rhythm ECG and determine recurrence burden before selecting preventive therapy. [19] |
| 2 | IV adenosine. [19] | Termination supports an AV-node-dependent mechanism but is not diagnostic; transient AV block may reveal atrial tachycardia. [18] |
| 3 | If refractory or recurrent: IV beta-blocker, diltiazem, or verapamil in a stable patient. [19] | Choose cautiously when blood pressure is vulnerable; slow calcium-channel blocker infusion has been studied as an alternative approach. [6][8] |
| 4 | Synchronized cardioversion when drug therapy fails, is contraindicated, or is infeasible. [4][19] | After conversion, pursue mechanism documentation and definitive therapy for recurrent symptomatic episodes. [16][19] |

## Separate AVNRT, AVRT, atrial tachycardia, and pre-excited rhythms

Mechanism changes medication safety, ablation target, and urgency of electrophysiology referral.

AVNRT and AVRT are common reentrant causes of PSVT. AVNRT depends on fast and slow AV nodal pathways, whereas AVRT uses an accessory pathway; ablation therefore targets the AV nodal slow pathway for AVNRT and the accessory pathway for AVRT. [16][22]

A resting ECG showing manifest pre-excitation should trigger arrhythmia-specialist referral. In a patient with WPW pattern and a stable regular narrow tachycardia consistent with orthodromic AVRT, use vagal maneuvers followed by adenosine as first-line therapy; beta-blockers or calcium-channel blockers are described as second-line agents, with cardioversion reserved for refractory rhythm. [17][19]

Do not extrapolate the orthodromic AVRT pathway to a wide-complex rhythm with possible pre-excitation or aberrancy. In this setting, uncertainty about rhythm mechanism is itself a reason to avoid routine AV-nodal blockade and use a wide-complex tachycardia approach. [17]

Suspect atrial tachycardia when abnormal P waves are identifiable or become apparent during transient AV block, particularly in patients with structural heart disease. Surface ECG interpretation and Holter analysis can refine the diagnosis and can direct mapping to anatomic regions of interest when catheter ablation is planned. [18][19]
- A regular narrow tachycardia differential includes sinus tachycardia, atrial tachycardia, atrial flutter with regular AV block, AVNRT, AVRT, and junctional tachycardia. [17]
- An irregular narrow tachycardia differential includes atrial fibrillation, flutter with variable block, multifocal atrial tachycardia, and ectopy. [17]
- Because focal atrial tachycardia may terminate with adenosine, use rhythm strips and atrial activation analysis rather than conversion alone to establish mechanism. [18]

*Mechanism-focused clues and management implications in SVT. [16][17][18][19]*

| Likely mechanism | Actionable clue | What it changes |
| --- | --- | --- |
| AVNRT | Abrupt episodes with neck pulsation; regular narrow-complex tachycardia is typical. [19] | AV-nodal termination strategy is appropriate when stable; definitive ablation targets the slow pathway. [16] |
| Orthodromic AVRT | WPW pattern in sinus rhythm plus regular narrow tachycardia. [17] | Vagal maneuvers then adenosine are first-line; refer for accessory-pathway assessment and ablation discussion. [17][16] |
| Focal atrial tachycardia | Atrial activity becomes visible during adenosine-induced or vagal AV block; structural heart disease increases suspicion. [18][19] | Do not infer mechanism solely from adenosine termination; use ECG/Holter characterization to plan mapping and treatment. [18] |
| Possible pre-excited or aberrant wide-complex tachycardia | Wide QRS or uncertainty whether conduction is via an accessory pathway. [17] | Avoid assuming a regular-SVT pathway; manage as undifferentiated wide-complex tachycardia. [17] |

## Choose ablation or medical suppression based on symptoms, pre-excitation, and patient preference

A documented episode should lead to a mechanism-specific plan rather than repeated unscheduled acute care.

Offer electrophysiology study and catheter ablation as first-line definitive treatment for symptomatic PSVT when the patient is an ablation candidate and prefers a curative strategy. Contemporary sources describe excellent success with relatively low complication rates for AVNRT and AVRT, and ablation can reduce recurrent hospitalization and reliance on long-term medication. [16][13]

For regular SVT of unknown mechanism, patients who are candidates for and prefer ablation should undergo electrophysiology study with catheter ablation. If medical therapy is selected, beta-blockers, diltiazem, or verapamil are options only in the absence of pre-excitation; flecainide or propafenone are options in the absence of structural heart disease. [19]

For patients who cannot undergo or decline ablation and do not respond to simpler agents, amiodarone, dofetilide, or sotalol are listed as lower-strength ongoing options; digoxin is an option only when pre-excitation is absent. These drugs require individualized selection because the source algorithm does not provide dosing or monitoring specifications. [19]

Manifest pre-excitation materially lowers the threshold for electrophysiology referral. Ablation may be considered even without symptoms when the accessory pathway has a short refractory period, and is strongly recommended for high-risk occupations. [16]
- Refer recurrent symptomatic PSVT, drug-refractory episodes, intolerable symptoms, syncope or presyncope, and manifest pre-excitation for electrophysiology evaluation. [7][16][19]
- Document a baseline sinus-rhythm ECG after conversion to identify pre-excitation and to support mechanism-specific referral. [17][19]
- For patients choosing observation or drug therapy, reassess after recurrence, emergency visits, worsening tolerance, or emergence of pre-excitation-related concerns; these events favor definitive EP evaluation. [16][19]

### Pregnancy

For PSVT during pregnancy, adenosine is the first-choice acute agent because of its very short half-life. IV metoprolol or propranolol are second-choice options; use verapamil cautiously when adenosine or beta-blockers are ineffective or contraindicated because of hypotension risk. Synchronized cardioversion is an option when drug therapy is ineffective or contraindicated. [7]
- Consider catheter ablation for drug-refractory, recurrent, or intolerable PSVT; avoid first-trimester ablation when possible, and fluoroscopy-free approaches may be feasible. [7]

*Ongoing management choices after documented regular SVT. [16][19]*

| Clinical situation | Preferred next step | Important restriction |
| --- | --- | --- |
| Symptomatic recurrent PSVT; patient accepts procedure | Electrophysiology study and catheter ablation. [16][19] | Define mechanism because AVNRT requires slow-pathway ablation and AVRT requires accessory-pathway ablation. [16] |
| No pre-excitation; medical therapy selected | Beta-blocker, diltiazem, or verapamil. [19] | Use only when pre-excitation is absent. [19] |
| No structural heart disease; medical therapy selected | Flecainide or propafenone may be considered. [19] | Do not apply this option when structural heart disease is present. [19] |
| Manifest pre-excitation | Arrhythmia-specialist referral and ablation discussion. [16][19] | Avoid the routine no-pre-excitation drug pathway. [19] |

## References
1. Diagnosis and management of supraventricular tachycardia - The BMJ — www.bmj.com — https://www.bmj.com/bmj/section-pdf/187706?path=%2Fbmj%2F345%2F7887%2FClinical_Review.full.pdf
2. Atrial fibrillation and supraventricular arrhythmias - Oxford Academic — academic.oup.com — https://academic.oup.com/book/38752/chapter/337365809
3. Hypertension and cardiac arrhythmias: a consensus document from ... — academic.oup.com — https://academic.oup.com/europace/article/19/6/891/3871445
4. Paroxysmal Supraventricular Tachycardia - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/paroxysmal-supraventricular-tachycardia
5. A Comparison of Adenosine and Verapamil for the Treatment of Supraventricular Tachycardia in the Prehospital Setting — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0196064495701796
6. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0300957209000574
7. Paroxysmal supraventricular tachycardia in... : Bali Journal of Anesthesiology — journals.lww.com — https://journals.lww.com/bjoa/fulltext/2023/07030/paroxysmal_supraventricular_tachycardia_in.14.aspx
8. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0300957209000574
9. Review of the 2019 European Society of Cardiology Guidelines for the management of patients with supraventricular tachycardia: What is new, and what has changed? — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6955050
10. Paroxysmal Supraventricular Tachycardia Treatment — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13425819
11. Clinical Practice Algorithms For Wolff-Parkinson-White Pattern in Pediatric Patients - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2025/08/13/10/27/clinical-practice-algorithms-for-wolff-parkinson-white-pattern-in-pediatric-patients
12. ESC Guidelines for Management of Supraventricular Tachycardia: Key Points - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/09/10/12/36/2019-esc-guidelines-for-supraventricular-tachycardia
13. Supraventricular Tachycardia - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441972
14. Atrioventricular Nodal Reentry Tachycardia - StatPearls - NCBI - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK499936
15. Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE) - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5248663
16. Paroxysmal Supraventricular Tachycardia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK507699
17. Wolff-Parkinson-White Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK554437
18. Electrocardiographic Diagnosis of Atrial Tachycardia: Classification, P‐Wave Morphology, and Differential Diagnosis with Other Supraventricular Tachycardias - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6931826
19. [PDF] SUPRAVENTRICULAR TACHYCARDIA (SVT) TOOLKIT — www.acc.org — https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2015/2015_SVT_Toolkit_ReferenceCard.pdf
20. Adenosine Should Be First-Line Treatment for Supraventricular Tachycardia - Annals of Emergency Medicine — www.annemergmed.com — https://www.annemergmed.com/article/S0196-0644(23)01346-X/pdf
21. ESC 365 - Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes — esc365.escardio.org — https://esc365.escardio.org/presentation/261892
22. Long-Term Clinical Outcomes From Catheter Ablation of SVT — publications.aap.org — https://publications.aap.org/aapgrandrounds/article/45/5/55/180511/Long-Term-Clinical-Outcomes-From-Catheter-Ablation
23. Focus on Diagnosis: Cardiac Arrhythmias in Children — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/31/9/375/33031/Focus-on-DiagnosisCardiac-Arrhythmias-in-Children
24. Cardiac Arrhythmias - AAP Publications — publications.aap.org — https://publications.aap.org/book/chapter-pdf/774731/aap_9781581108552-ch09.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.